CDKN2A and colorectal cancer: Moreover, thorough examinations of immune infiltration and biological functionalities have demonstrated the potential of CDKN2A as a viable therapeutic target for colorectal cancer and may offer valuable insights for PD-1-mediated immunotherapy.